Barclays PLC Sells 681,431 Shares of Catalent, Inc. (NYSE:CTLT)

Barclays PLC lowered its holdings in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 13.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 4,284,643 shares of the company's stock after selling 681,431 shares during the period. Barclays PLC owned about 2.36% of Catalent worth $259,519,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Brooklyn Investment Group purchased a new position in shares of Catalent in the third quarter worth about $31,000. Sentry Investment Management LLC bought a new stake in Catalent in the third quarter valued at approximately $53,000. Longfellow Investment Management Co. LLC boosted its stake in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock valued at $55,000 after purchasing an additional 305 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its holdings in shares of Catalent by 57.5% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company's stock worth $72,000 after purchasing an additional 431 shares during the last quarter. Finally, Intact Investment Management Inc. bought a new stake in Catalent during the 3rd quarter valued at $73,000.

Analysts Set New Price Targets

A number of equities analysts have issued reports on CTLT shares. StockNews.com cut shares of Catalent from a "hold" rating to a "sell" rating in a research report on Tuesday. Baird R W lowered Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. William Blair restated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Robert W. Baird reissued a "neutral" rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. Based on data from MarketBeat, Catalent currently has an average rating of "Hold" and a consensus target price of $63.40.

Insider Transactions at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company's stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the business's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares of the company's stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 in the last quarter. 0.31% of the stock is owned by insiders.

Catalent Stock Down 0.2 %

CTLT traded down $0.11 during midday trading on Tuesday, reaching $62.26. The company's stock had a trading volume of 2,129,004 shares, compared to its average volume of 2,052,697. Catalent, Inc. has a 1 year low of $36.74 and a 1 year high of $62.50. The stock's 50-day moving average is $60.15 and its 200-day moving average is $58.85. The firm has a market capitalization of $11.30 billion, a price-to-earnings ratio of -27.55, a PEG ratio of 2.46 and a beta of 1.15. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same quarter in the previous year, the company earned ($0.10) EPS. The business's quarterly revenue was up 4.2% on a year-over-year basis. As a group, research analysts expect that Catalent, Inc. will post 0.84 EPS for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.